Deborah Soong1, Justin Taylor1

  • 1Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami.

NEJM evidence
|February 6, 2024
PubMed
概括

毛细胞白血病 (HCL) 是一种罕见的B细胞癌,具有近乎普遍的BRAF突变. 这种突变驱动MAPK通路,使HCL对BRAF向疗法的高度反应.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K